Literature DB >> 20677822

GSK4112, a small molecule chemical probe for the cell biology of the nuclear heme receptor Rev-erbα.

Daniel Grant1, Lei Yin, Jon L Collins, Derek J Parks, Lisa A Orband-Miller, G Bruce Wisely, Shree Joshi, Mitchell A Lazar, Timothy M Willson, William J Zuercher.   

Abstract

The identification of nonporphyrin ligands for the orphan nuclear receptor Rev-erbα will enable studies of its role as a heme sensor and regulator of metabolic and circadian signaling. We describe the development of a biochemical assay measuring the interaction between Rev-erbα and a peptide from the nuclear receptor corepressor-1 (NCoR). The assay was utilized to identify a small molecule ligand for Rev-erbα, GSK4112 (1), that was competitive with heme. In cells, 1 profiled as a Rev-erbα agonist in cells to inhibit expression of the circadian target gene bmal1. In addition, 1 repressed the expression of gluconeogenic genes in liver cells and reduced glucose output in primary hepatocytes. Therefore, 1 is useful as a chemical tool to probe the function of Rev-erbα in transcriptional repression, regulation of circadian biology, and metabolic pathways. Additionally, 1 may serve as a starting point for design of Rev-erbα chemical probes with in vivo pharmacological activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20677822     DOI: 10.1021/cb100141y

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  49 in total

Review 1.  Circadian molecular clock in lung pathophysiology.

Authors:  Isaac K Sundar; Hongwei Yao; Michael T Sellix; Irfan Rahman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-09-11       Impact factor: 5.464

2.  Binding mode prediction and MD/MMPBSA-based free energy ranking for agonists of REV-ERBα/NCoR.

Authors:  Yvonne Westermaier; Sergio Ruiz-Carmona; Isabelle Theret; Françoise Perron-Sierra; Guillaume Poissonnet; Catherine Dacquet; Jean A Boutin; Pierre Ducrot; Xavier Barril
Journal:  J Comput Aided Mol Des       Date:  2017-07-15       Impact factor: 3.686

3.  Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB.

Authors:  Douglas Kojetin; Yongjun Wang; Theodore M Kamenecka; Thomas P Burris
Journal:  ACS Chem Biol       Date:  2010-11-10       Impact factor: 5.100

Review 4.  Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment.

Authors:  Gabriele Sulli; Michael Tun Yin Lam; Satchidananda Panda
Journal:  Trends Cancer       Date:  2019-08-03

Review 5.  Nuclear receptor Rev-erbα: up, down, and all around.

Authors:  Logan J Everett; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2014-07-22       Impact factor: 12.015

6.  Molecular mechanisms of transcriptional control by Rev-erbα: An energetic foundation for reconciling structure and binding with biological function.

Authors:  Anaïs Vaissière; Sylvie Berger; Deborah Harrus; Catherine Dacquet; Albane Le Maire; Jean A Boutin; Gilles Ferry; Catherine A Royer
Journal:  Protein Sci       Date:  2015-06-11       Impact factor: 6.725

7.  Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function.

Authors:  Anne Bugge; Dan Feng; Logan J Everett; Erika R Briggs; Shannon E Mullican; Fenfen Wang; Jennifer Jager; Mitchell A Lazar
Journal:  Genes Dev       Date:  2012-04-01       Impact factor: 11.361

Review 8.  Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases.

Authors:  Gabriele Sulli; Emily N C Manoogian; Pam R Taub; Satchidananda Panda
Journal:  Trends Pharmacol Sci       Date:  2018-07-27       Impact factor: 14.819

9.  Deleted in breast cancer 1 (DBC1) protein regulates hepatic gluconeogenesis.

Authors:  Veronica Nin; Claudia C S Chini; Carlos Escande; Verena Capellini; Eduardo N Chini
Journal:  J Biol Chem       Date:  2014-01-10       Impact factor: 5.157

Review 10.  REV-ERB and ROR nuclear receptors as drug targets.

Authors:  Douglas J Kojetin; Thomas P Burris
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.